(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 February 2012 (23.02.2012)

PCT

(10) International Publication Number
WO 2012/022982 A2

(51) **International Patent Classification**:
C07K 16/00 (2006.01)

(21) **International Application Number**:
PCT/GB2011/051563

(22) **International Filing Date**:
19 August 2011 (19.08.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
1014033.3 20 August 2010 (20.08.2010) GB

(71) **Applicants** *(for all designated States except US)*: **UCB PHARMA S.A.** [BE/BE]; 60 Allée de la Recherche, B-1070 Brussels (BE). **PETERS, Shirley Jane** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **HUMPHREYS, David Paul** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **ADAMS, Ralph** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **HEADS, James** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(74) **Agent**: **THOMPSON, John**; UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2012/022982 A2

(54) **Title**: IMPROVED ANTIBODIES OF THE CLASS IGG4

Figure 1b

Light chain	C_L			
Human κ	FNRGEC (SEQ ID NO:3)			
Heavy chain	**C_H1 (N-term)**	**UPPER**	**CORE**	**LOWER**
Human IgGγ1	TAPSSKSTS (SEQ ID NO:4)	EPKSCDKTHT (SEQ ID NO:5)	CPPC P	APELLGGP
Human IgGγ2	IAPCSRSTS (SEQ ID NO:6)	ERK (SEQ ID NO:7)	CCVECPPCP	APPVA GP
Human IgGγ3	IAPCSRSTS (SEQ ID NO:8)	ELKTPLGDTTHT (SEQ ID NO:9)	CPRCP(EPKSCDTPPPCPRCP)$_3$	APELLGGP
Human IgGγ4	IAPCSRSTS ↑ C127 (SEQ ID NO:10)	ESKYGPP ↑ G230 (SEQ ID NO:11)	CPSCP ↑ C239 ↑ C242	APEFLGGP
Heavy chain	**C_H1 (N-term)**	**Hinge**		
Human IgD	IISGCRHPK (SEQ ID NO:67)	(E)SPKAQASSVPTAQPQAEGSLAKATTAPATTRNT (SEQ ID NO:68)		
Heavy chain	**C_H1 (N-term)**	**C_H1 (C-term)**		**C_H2 (N-term)**
Human IgM	LVSCENSPS (SEQ ID NO:69)	EKNVPLP (SEQ ID NO:70)		(V) IASLPPKVSV (SEQ ID NO:71)

(57) **Abstract**: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a C_H1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the C_H1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.